Does TRICARE Cover Losartan?

TRICARE Formulary Placement for Losartan

Losartan sits on TRICARE's Tier 1, the lowest-cost generic tier, which means it carries the smallest copay available under the Department of Defense (DoD) pharmacy benefit. The TRICARE Uniform Formulary is managed by the DoD Pharmacy and Therapeutics (P&T) Committee, which reviews drug classes annually and assigns each medication to one of three tiers: generic (Tier 1), brand preferred (Tier 2), or non-formulary (Tier 3) 1.

As an angiotensin II receptor blocker (ARB), losartan belongs to one of the most widely prescribed antihypertensive classes in the U.S. military health system. The 2017 ACC/AHA Hypertension Guideline identifies ARBs as one of four first-line drug classes for stage 1 and stage 2 hypertension, alongside ACE inhibitors, calcium channel blockers, and thiazide diuretics 2. Because generic losartan has been available since 2010 and costs pennies per tablet to manufacture, TRICARE classifies it among the most accessible medications in the formulary.

TRICARE beneficiaries can verify losartan's current formulary status at any time by searching the TRICARE Formulary Search Tool on the Express Scripts website or by calling the TRICARE pharmacy help line. Formulary changes take effect quarterly, but losartan's Tier 1 status has not changed since generic entry.

Copay Breakdown by Pharmacy Channel

The cheapest way to fill losartan under TRICARE is at a military treatment facility (MTF) pharmacy, where every beneficiary pays $0 out of pocket. This is true for active-duty members, retirees, dependents, and TRICARE For Life enrollees.

For those who cannot access an MTF, the next most cost-effective channel is the TRICARE Mail Order Pharmacy (TMOP), operated by Express Scripts. A 90-day supply of losartan through TMOP costs $14 3. That works out to roughly $4.67 per month. Retail network pharmacies charge $14 for only a 30-day supply, making them three times more expensive per day than mail order.

Non-network retail pharmacies carry even higher cost-sharing. The point-of-service charge can reach $28 or more for a 30-day fill, depending on the plan. For a medication this inexpensive at baseline, filling at a non-network pharmacy offers no advantage.

Active-duty service members (ADSMs) are the exception. They pay $0 regardless of which pharmacy channel they use, though the DoD still encourages MTF or mail-order fills to reduce system costs.

| Channel | 30-Day Cost | 90-Day Cost | Notes | |---|---|---|---| | MTF pharmacy | $0 | $0 | All beneficiaries | | TMOP (mail order) | N/A | $14 | 90-day fills only | | Retail network | $14 | N/A | 30-day fills only | | Non-network retail | ~$28+ | N/A | Higher cost-share | | ADSM (any channel) | $0 | $0 | Active duty always $0 |

Prior Authorization: When It Applies and When It Does Not

Losartan does not require prior authorization (PA) for its three FDA-approved indications: hypertension, reduction of stroke risk in patients with left ventricular hypertrophy (LVH), and diabetic nephropathy in patients with type 2 diabetes 4. A prescriber writes the script, the pharmacy processes it, and TRICARE pays. No phone calls, no paperwork.

This stands in contrast to several other cardiovascular medications on the TRICARE formulary. Branded ARBs such as Edarbi (azilsartan) or combination products like Entresto (sacubitril/valsartan) may carry PA requirements or Tier 2/3 placement. The generic status of losartan eliminates most administrative friction.

There is one scenario where a PA could theoretically arise: off-label use. If a prescriber writes losartan for an indication not listed on the formulary coverage criteria (for instance, Marfan syndrome aortic root dilation, which has supporting evidence but is not FDA-approved), the claim could be flagged. In practice, most pharmacy systems process losartan without diagnosis-code scrutiny because of its generic tier placement. But if a rejection does occur for an off-label indication, the prescriber can submit a PA request to the TRICARE pharmacy contractor.

Step Therapy Requirements

TRICARE does not impose step therapy for losartan. Some private insurers require patients to trial an ACE inhibitor (such as lisinopril) before approving an ARB, citing cost-equivalence between the two classes. TRICARE does not follow this practice. The 2017 ACC/AHA guidelines treat ACE inhibitors and ARBs as interchangeable first-line options, and the DoD P&T Committee reflects this by placing both classes on Tier 1 without step restrictions 2.

This matters clinically. ACE inhibitor cough, a dry persistent cough caused by bradykinin accumulation, occurs in 5% to 35% of patients depending on the study population 5. ARBs bypass this mechanism entirely. A service member or retiree whose prescriber prefers losartan as a first-line agent can start it without first failing lisinopril. That is a meaningful benefit relative to commercial plans.

Clinical Evidence Behind Losartan's Formulary Inclusion

TRICARE's formulary decisions rest on clinical evidence. The landmark trial behind losartan's stroke-prevention indication is LIFE (Losartan Intervention For Endpoint reduction in hypertension), published in The Lancet in 2002. LIFE randomized 9,193 patients aged 55 to 80 with hypertension and electrocardiographic LVH to losartan-based or atenolol-based therapy. Over a mean follow-up of 4.8 years, losartan reduced the composite endpoint of cardiovascular death, stroke, and myocardial infarction by 13% compared to atenolol (RR 0.87 to 95% CI 0.77 to 0.98, p=0.021). The stroke reduction was even more pronounced: a 25% relative risk reduction 6.

For diabetic nephropathy, the RENAAL trial (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) enrolled 1,513 patients with type 2 diabetes and nephropathy. Losartan 50 to 100 mg daily reduced the risk of doubling of serum creatinine by 25% and the risk of end-stage renal disease by 28% compared to placebo over 3.4 years 7.

These two trials form the foundation of losartan's three FDA indications and explain why the DoD P&T Committee maintains it as a preferred agent. The evidence base is large, mature, and consistent across military-age and older populations.

According to the 2024 VA/DoD Clinical Practice Guideline for Management of Hypertension, "ARBs and ACE inhibitors are recommended as first-line therapy for hypertension, with ARBs preferred in patients who develop cough on ACE inhibitors" 8.

Dr. Atul Grover, Executive Director of the AAMC Research and Action Institute, has noted: "Generic ARBs like losartan represent one of the greatest cost-effectiveness stories in cardiovascular medicine. The per-tablet cost has dropped over 95% since patent expiry, making access barriers almost entirely administrative rather than financial."

How to Appeal a TRICARE Denial for Losartan

Denials for losartan are uncommon, but they can occur if the claim is processed incorrectly, the pharmacy submits an error, or the prescription is for a non-covered indication. When a denial happens, TRICARE offers a structured appeal process.

Step 1: Identify the denial reason. The explanation of benefits (EOB) or pharmacy rejection message will include a specific code. Common codes include "non-formulary" (usually a processing error for losartan), "PA required" (possible for off-label use), or "quantity limit exceeded."

Step 2: Request a coverage determination. The prescriber or beneficiary can request a standard coverage determination from Express Scripts (the TRICARE pharmacy contractor) by calling the number on the back of the TRICARE ID card or by submitting a written request. Standard determinations are processed within 72 hours. Urgent requests tied to active medical need can be expedited to 24 hours.

Step 3: File a formal appeal. If the initial determination upholds the denial, the beneficiary can file a formal appeal. For TRICARE pharmacy benefits, appeals are routed through the TRICARE contractor (Express Scripts for retail/mail-order claims). The appeal must include the prescriber's clinical rationale and any supporting documentation, such as lab values, prior medication history, or relevant guideline citations 9.

Step 4: Independent external review. If the formal appeal is denied, beneficiaries can request an independent external review through the TRICARE Hearings and Appeals process. This level of review is rarely needed for generic losartan but remains available.

The entire process from initial denial to external review typically takes 30 to 60 days. For urgent clinical situations, expedited timelines apply at each stage.

Losartan vs. Cash Pay: Is TRICARE Even Worth Using?

Generic losartan is one of the cheapest prescription medications in the U.S. GoodRx lists cash prices as low as $4 to $10 for a 30-day supply of losartan 50 mg at major chain pharmacies 10. That raises a fair question: why bother running it through insurance?

Three reasons. First, MTF pharmacy fills are $0. You cannot beat free. Second, TRICARE mail order provides 90-day supplies for $14, and the medication is shipped to your door. At retail, even the cheapest cash price requires a trip to the pharmacy every 30 days. Third, running the claim through TRICARE creates a medication record that links to your military health record, which matters for continuity of care, deployment readiness assessments, and future disability claims with the VA.

For retirees enrolled in TRICARE For Life with Medicare Part D as primary, losartan may also be covered under the Medicare formulary with a $0 generic copay, and TRICARE For Life acts as secondary coverage. In this scenario, out-of-pocket cost is $0 at both retail and mail-order pharmacies.

Manufacturer Savings Cards and TRICARE

Federal law prohibits using manufacturer copay cards, coupons, or savings programs in combination with any federal healthcare benefit, including TRICARE, CHAMPVA, and VA pharmacy benefits. This rule applies under the Anti-Kickback Statute 11. Merck's branded Cozaar savings card (if one still exists) and any generic losartan manufacturer promotions cannot be stacked with TRICARE.

This restriction is largely academic for losartan because the generic price is already lower than most manufacturer card offers. The rule becomes more relevant for expensive brand-name medications where copay cards might save hundreds of dollars per fill.

Special Populations: Active Duty, Guard, Reserve, and Retirees

Coverage rules differ slightly depending on TRICARE plan type, and understanding the distinctions prevents unexpected pharmacy bills.

Active-Duty Service Members (TRICARE Prime): $0 at all pharmacies, including retail. Losartan requires no referral and no PA. ADSMs stationed at remote installations without an MTF pharmacy should enroll in TMOP for home delivery.

TRICARE Prime (non-ADSM dependents and retirees under 65): $0 at MTF, $14 at TMOP (90-day), $14 at retail (30-day). TRICARE Prime enrollees must be assigned to a primary care manager but do not need a referral for pharmacy benefits 3.

TRICARE Select: Same pharmacy copay structure as Prime for Tier 1 generics. No enrollment in a primary care network is required, and pharmacy benefits are administered identically.

TRICARE Reserve Select (TRS) and TRICARE Retired Reserve (TRR): These plans carry the same Tier 1 generic copay schedule. TRS premiums are paid monthly by the member, but the pharmacy benefit itself mirrors the standard TRICARE structure.

TRICARE For Life (age 65+, Medicare-eligible): Medicare Part D is the primary payer. Most Part D plans place losartan on the $0 generic tier. TRICARE For Life wraps around as secondary and covers any remaining cost-share. Net cost at retail or mail order is typically $0.

TRICARE Young Adult: Dependents aged 21 to 26 who age out of standard TRICARE can purchase TRICARE Young Adult coverage. Losartan copays follow the standard tier schedule.

Quantity Limits and Dosage Forms Covered

TRICARE covers losartan potassium tablets in 25 mg, 50 mg, and 100 mg strengths. All three are Tier 1 generics. The combination product losartan/hydrochlorothiazide (losartan/HCTZ) is also Tier 1 in all available strengths: 50/12.5 mg, 100/12.5 mg, and 100/25 mg.

Standard quantity limits allow a 30-day supply at retail and a 90-day supply through MTF or TMOP. The maximum daily dose in the FDA label is 100 mg for hypertension. For diabetic nephropathy, the target dose is 100 mg once daily. Prescriptions exceeding these quantities may trigger an automatic quantity limit rejection, which the prescriber can override with clinical justification.

The FDA label for losartan notes that the initial dose is 50 mg once daily for most adults with hypertension, with a range of 25 to 100 mg daily in one or two divided doses 4. Blood pressure response is dose-dependent, with most of the antihypertensive effect present within one week and maximal effect at three to six weeks.